Management of bleeding disorders

Basic science

F. A. Ofosu, E. Santagostino, S. Grancha, P. Marco

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Development of factor VIII (FVIII) inhibitors is the most severe and challenging complication of haemophilia A treatment and represents the highest economic burden for a chronic disease. Therefore, major research efforts are ongoing to optimize the therapeutic approaches able to minimize this complication. FVIII inhibitors have variable immuno-reactivity against different FVIII concentrates and generally have a lower reactivity against von Willebrand factor (VWF)-containing FVIII concentrates than plasma-derived FVIII (pdFVIII) or recombinant FVIII (rFVIII) that are devoid of VWF, in particular when the inhibitors are directed against the light chain of FVIII. This paper provides an overview of several in vitro and in vivo studies that compared three clinically available clinical FVIII products (Kogenate®, Bayer AG, Leverkusen, Germany; Advate®, Baxter Healthcare, Zurich, Switzerland; and Fanhdi®, Grifols S.A., Barcelona, Spain) in order to evaluate the functional actvity of the FVIII fractions in rFVIII that cannot bind VWF; explore the use of the thrombin generation assay (TGA) as a potential tool for optimizing the choice of FVIII concentrate for use in haemophilia A patients with inhibitors; compare the kinetics of the interactions between anti-FVIII antibodies and FVIII both in the presence/absence of VWF, using surface plasmon resonance.

Original languageEnglish
Pages (from-to)8-14
Number of pages7
JournalHaemophilia
Volume18
Issue numberSUPPL. 2
DOIs
Publication statusPublished - May 2012

Fingerprint

Factor VIII
Hemorrhage
Hemophilia A
von Willebrand Factor
Surface Plasmon Resonance
Switzerland
Thrombin
Spain
Germany
Chronic Disease
Economics
Delivery of Health Care
Light
Antibodies

Keywords

  • FVIII concentrate
  • Haemophilia A
  • In vitro studies
  • In vivo studies
  • Thrombin generation assay
  • Von willebrand factor

ASJC Scopus subject areas

  • Hematology
  • Genetics(clinical)

Cite this

Management of bleeding disorders : Basic science. / Ofosu, F. A.; Santagostino, E.; Grancha, S.; Marco, P.

In: Haemophilia, Vol. 18, No. SUPPL. 2, 05.2012, p. 8-14.

Research output: Contribution to journalArticle

Ofosu, F. A. ; Santagostino, E. ; Grancha, S. ; Marco, P. / Management of bleeding disorders : Basic science. In: Haemophilia. 2012 ; Vol. 18, No. SUPPL. 2. pp. 8-14.
@article{85188d05ef0a44e3a78f3342e1267304,
title = "Management of bleeding disorders: Basic science",
abstract = "Development of factor VIII (FVIII) inhibitors is the most severe and challenging complication of haemophilia A treatment and represents the highest economic burden for a chronic disease. Therefore, major research efforts are ongoing to optimize the therapeutic approaches able to minimize this complication. FVIII inhibitors have variable immuno-reactivity against different FVIII concentrates and generally have a lower reactivity against von Willebrand factor (VWF)-containing FVIII concentrates than plasma-derived FVIII (pdFVIII) or recombinant FVIII (rFVIII) that are devoid of VWF, in particular when the inhibitors are directed against the light chain of FVIII. This paper provides an overview of several in vitro and in vivo studies that compared three clinically available clinical FVIII products (Kogenate{\circledR}, Bayer AG, Leverkusen, Germany; Advate{\circledR}, Baxter Healthcare, Zurich, Switzerland; and Fanhdi{\circledR}, Grifols S.A., Barcelona, Spain) in order to evaluate the functional actvity of the FVIII fractions in rFVIII that cannot bind VWF; explore the use of the thrombin generation assay (TGA) as a potential tool for optimizing the choice of FVIII concentrate for use in haemophilia A patients with inhibitors; compare the kinetics of the interactions between anti-FVIII antibodies and FVIII both in the presence/absence of VWF, using surface plasmon resonance.",
keywords = "FVIII concentrate, Haemophilia A, In vitro studies, In vivo studies, Thrombin generation assay, Von willebrand factor",
author = "Ofosu, {F. A.} and E. Santagostino and S. Grancha and P. Marco",
year = "2012",
month = "5",
doi = "10.1111/j.1365-2516.2012.02795.x",
language = "English",
volume = "18",
pages = "8--14",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Management of bleeding disorders

T2 - Basic science

AU - Ofosu, F. A.

AU - Santagostino, E.

AU - Grancha, S.

AU - Marco, P.

PY - 2012/5

Y1 - 2012/5

N2 - Development of factor VIII (FVIII) inhibitors is the most severe and challenging complication of haemophilia A treatment and represents the highest economic burden for a chronic disease. Therefore, major research efforts are ongoing to optimize the therapeutic approaches able to minimize this complication. FVIII inhibitors have variable immuno-reactivity against different FVIII concentrates and generally have a lower reactivity against von Willebrand factor (VWF)-containing FVIII concentrates than plasma-derived FVIII (pdFVIII) or recombinant FVIII (rFVIII) that are devoid of VWF, in particular when the inhibitors are directed against the light chain of FVIII. This paper provides an overview of several in vitro and in vivo studies that compared three clinically available clinical FVIII products (Kogenate®, Bayer AG, Leverkusen, Germany; Advate®, Baxter Healthcare, Zurich, Switzerland; and Fanhdi®, Grifols S.A., Barcelona, Spain) in order to evaluate the functional actvity of the FVIII fractions in rFVIII that cannot bind VWF; explore the use of the thrombin generation assay (TGA) as a potential tool for optimizing the choice of FVIII concentrate for use in haemophilia A patients with inhibitors; compare the kinetics of the interactions between anti-FVIII antibodies and FVIII both in the presence/absence of VWF, using surface plasmon resonance.

AB - Development of factor VIII (FVIII) inhibitors is the most severe and challenging complication of haemophilia A treatment and represents the highest economic burden for a chronic disease. Therefore, major research efforts are ongoing to optimize the therapeutic approaches able to minimize this complication. FVIII inhibitors have variable immuno-reactivity against different FVIII concentrates and generally have a lower reactivity against von Willebrand factor (VWF)-containing FVIII concentrates than plasma-derived FVIII (pdFVIII) or recombinant FVIII (rFVIII) that are devoid of VWF, in particular when the inhibitors are directed against the light chain of FVIII. This paper provides an overview of several in vitro and in vivo studies that compared three clinically available clinical FVIII products (Kogenate®, Bayer AG, Leverkusen, Germany; Advate®, Baxter Healthcare, Zurich, Switzerland; and Fanhdi®, Grifols S.A., Barcelona, Spain) in order to evaluate the functional actvity of the FVIII fractions in rFVIII that cannot bind VWF; explore the use of the thrombin generation assay (TGA) as a potential tool for optimizing the choice of FVIII concentrate for use in haemophilia A patients with inhibitors; compare the kinetics of the interactions between anti-FVIII antibodies and FVIII both in the presence/absence of VWF, using surface plasmon resonance.

KW - FVIII concentrate

KW - Haemophilia A

KW - In vitro studies

KW - In vivo studies

KW - Thrombin generation assay

KW - Von willebrand factor

UR - http://www.scopus.com/inward/record.url?scp=84860293177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860293177&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2516.2012.02795.x

DO - 10.1111/j.1365-2516.2012.02795.x

M3 - Article

VL - 18

SP - 8

EP - 14

JO - Haemophilia

JF - Haemophilia

SN - 1351-8216

IS - SUPPL. 2

ER -